Treatment of acute leukemia in children with and without folic acid antagonists

Poncher, Henry G.; Waisman, Harry A.; Richmond, Julius B.; Horák, Ondřej; Limarzi, Louis R.

doi:10.1016/s0022-3476(52)80120-9

Cited by 20 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although dermatologic toxicities from cancer treatments have been well described in adults, there are very few studies on such effects in children. [1][2][3] Cardoze-Torres et al 1 xerosis (35%) to be the most common cutaneous adverse effects, but we also observed that inflammatory dermatoses (51%) and nail changes (20%) were frequent. This mirrors the reported incidence (64.3%) of alopecia in adults receiving cancer chemotherapy.…”

Section: Discussionsupporting

confidence: 55%

Cutaneous manifestations in pediatric oncology patients

Özkur

Sert

Altunay

et al. 2020

Pediatric Dermatology

View full text Add to dashboard Cite

Background/Objectives: Oncology patients present with various skin manifestations related to primary disease and treatments. Although these skin toxicities are well described in adults, studies of pediatric oncology patients are limited. The objective of this study was to evaluate the cutaneous findings in pediatric oncology patients receiving chemotherapy. Methods: In this prospective cohort study conducted from December 2018 to March 2020, all pediatric oncology patients were examined and patients who had a dermatologic finding at any point during their treatments were recorded. Dermatologic examinations were performed by the same dermatologists, and biopsy and microbiologic tests were performed according to clinical need. Patients were grouped according to their oncologic diagnoses and types of chemotherapies. Results: A total of 80 patients with a mean age of 9.1 ± 5.0 years were included in the study. Seventy-five (93.7%) of them developed a dermatologic manifestation during the study period. Most of the patients had hematologic malignancies (n = 48, 60%). Antimetabolites were the most frequently used class of chemotherapeutic agents. Anagen effluvium was the most common dermatologic finding (61.3%, n = 49), followed by inflammatory dermatoses (51.2%, n = 41, most commonly diaper dermatitis in 33 patients), xerosis (35%, n = 28), and nail changes (20%, n = 16, most commonly nail pigmentation in seven patients). Mucositis was seen in 13 (16.2%) patients. Five patients (6.2%) had drug-induced cutaneous hyperpigmentation, and five (6.2%) had toxic erythema of chemotherapy. The highest percentage of xerosis (45.4%) was detected in patients using antitumor antibiotics, whereas inflammatory dermatoses were observed more in patients using antimetabolites (48.6% of patients using antimetabolites), and pigmentation changes were more frequently detected in patients using alkylating agents. Conclusion: Identification, diagnosis, and treatment of these reactions are important to dermatologists and oncologists so that appropriate management may be provided to pediatric oncology patients.

show abstract

Section: Discussionsupporting

confidence: 55%

Cutaneous manifestations in pediatric oncology patients

Özkur

Sert

Altunay

et al. 2020

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…Oral mucositis is another prevalent toxicity that was described with early chemotherapy agents. 41,42 Characterized by erythema, edema, and ulceration of oral mucosa, its incidence varies depending on the chemotherapy drug, dose, and scheduling. Mucosal changes typically manifest within the first week of treatment.…”

Section: Dermatologic Adverse Events Caused By Conventional Cytotoxicmentioning

confidence: 99%

The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

Balagula

Rosen

Lacouture

2011

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…It was present in only 20% of the 334 cases studied by Schwab and Weiss (1935). Since the use of more effective chemotherapy, cases of children receiving such treatment who have developed signs of intracranial involvement are being reported (Poncher, Waisman, Richmond, Horak and Limarzi, 1952;Sansone, 1954;Sullivan, 1957;Meneely, 1958;Whiteside, Philips, Dargeon and Burchenal, 1958;Cramblett, 1959;Murphy, 1959). Hamilton and Elion (1954) showed that the concentration of labelled 6-mercaptopurine in cerebral tissue was only one-tenth of that found in blood and that an even greater differential existed between its concentration in blood and cerebrospinal fluid.…”

Section: Commentmentioning

confidence: 99%